top of page

ABSTRACTS

For details click on the respective title:

Reviewer Decision
Presenter
Title
Format
Jimmy K. Lee, MD
Effectiveness of Nitric Oxide for bacterial and fungal activity in contact lens systems
Amir Akhavanrezayat, MD
Longitudinal Assessment of Patients With Anterior Scleritis Using Scleral Area Vessel Density
Daphne Haim-Langford Ph.D
TRS (Tuftsin-Phosphorylcholine) platform technology for the topical treatment of ocular inflammation
David Chu, MD
Intraocular Pressure Following Suprachoroidal Administration of Triamcinolone Acetonide Suspension: Results from the Phase 3 PEACHTREE Clinical Trial
Doran Spencer
Pseudoguttata in uveitis: a new diagnostic criterion?
Gerard Lutty
A role for choroidal mast cell degranulation in geographic atrophy
Gunay Uludag, MD
Posterior Segment Manifestations in Patients with HLA-B27-associated Uveitis
Doan Luong Hien, ND
Correlation between change in aqueous flare assessment using laser flare photometer to change in BCVA and clinical grade
John C Affeldt, MD
Novel Use of HP Acther Gel in the Treatment of Peripheral Ulcerative Keratitis
Jordan Ueberroth, MD
Delayed Acceleration of Acute Flare Severity in Patients with HLA-B27 Associated Anterior Uveitis
Ron Neumann
Grading Image Scale (G.I.S) for anterior chamber cell count in patients with anterior uveitis.
Jong Park, MD
A Distinct Pattern of Choroidal Lesions in Multifocal Choroiditis and Pan-uveitis Determined by Heatmap Analysis
Quan Dong Nguyen, MD, MSc
Systemic Therapy and the Efficacy of CLS-TA: Results from the Phase 3 PEACHTREE Clinical Trial
Ryoji Yanai, MD, PhD
Early intraocular pressure‑lowering effects of the Rho kinase inhibitor ripasudil in patients with uveitic glaucoma
Sohail Halim, MD
Sohail Halim, MD
Sophaktra Chea, MD
Predictors of visual outcomes in uveitic macular edema
Wataru Matsumiya, MD
Evaluating optical coherence tomography findings as potential biomarkers in central nervous system lymphoma with or without ocular involvement
Zdenka Haskova, MD, PhD
Efficacy and safety of satralizumab from two phase 3 trials in neuromyelitis optica spectrum disorder
bottom of page